SGLT-2 inhibitors (gliflozins) are a new therapeutic class for managing Type 2 diabetes, acting by their glucoretic effect. Along with their glycemic action, these agents likewise exhibit cardiovascular and renal benefits.
What does this article bring up for us?
This article provides an update on the clinical usefulness of SLGT-2 inhibitors, including their cardiovascular and renal benefits. Another aim of this article is to better define the place of SGLT-2 inhibitors in the currently used Type 2 diabetes management algorithm.
Key words
SGLT-2 inhibitors, mode of action, glycemic control, heart, kidney, side effect